Company: SCLXW
Filing Date: 2025-12-29
Form Type: 424B3
Source: 0001193125-25-335429
Chunk: 13

Company: Scilex Holding Co
Filing Date: 2025-12-29
Form: 424B3
Chunk 13
---
 to the Effective Time were, without 
 any action on the part of the holder, separated automatically into its component securities, comprised of one share of Common Stock and one-half of one warrant to purchase one share of Common Stock.                                                                                                             |

| • |     | “Vickers” means Vickers Vantage Corp. I, our predecessor company. |

| • |     | “Vickers Ordinary Shares” means (i) the ordinary shares, par value $0.0001 per share, of  
 Vickers prior to the Domestication and (ii) the Common Stock following the Domestication. |

| • |     | “Yorkville” means YA II PN, Ltd., a Cayman Islands exempt limited partnership. |

8

PROSPECTUS SUMMARY

This summary highlights selected information that is presented in greater detail elsewhere in this prospectus. Because it is only a summary, it does not contain all of the information you should consider before investing in our securities and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information included elsewhere in this prospectus. Before you decide whether to purchase our securities, you should read this entire prospectus carefully, including the sections of this prospectus titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” You should also carefully read the information in this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part.

Background of Issuance of the Exchange Warrants

On October 8, 2024, we issued warrants to purchase shares of Common Stock in the initial aggregate amount of 3,750,000 shares (on a pre-Reverse Stock Split basis, which were exercisable for 107,142 shares on a post-Reverse Stock Split basis) to the Tranche B Investors. Oramed Pharmaceuticals Inc. waived its right to participate in the warrant
exchange. The October 2024 Noteholder Warrants were issued pursuant to the Original Registration Statement, which registration statement was subsequently converted to the Continuation Registration Statement due to the Company’s ineligibility
to use a registration statement on Form S-3.

On July 22, 2025, we entered into Warrant
Exchange Agreements with each Tranche B Investor (copies of which are filed as an exhibit to the registration statement of which this prospectus forms a part) pursuant to which, at the closing of the transactions contemplated thereby and in reliance
on the exemption from